Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.
The company was incorporated in 2018 and is headquartered in Foster City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 24 | -0.30 Increased by +47.74% | -0.45 Increased by +33.80% |
| Aug 7, 24 | -0.52 Increased by +73.20% | -0.47 Decreased by -10.64% |
| May 8, 24 | -0.54 Increased by +32.50% | -0.48 Decreased by -12.50% |
| Feb 28, 24 | -0.66 Increased by +33.33% | -0.24 Decreased by -175.00% |
| Nov 2, 23 | -0.57 Increased by +44.12% | -0.63 Increased by +9.52% |
| Aug 3, 23 | -1.94 Decreased by -130.95% | -0.80 Decreased by -142.50% |
| May 4, 23 | -0.80 Increased by +31.62% | -0.94 Increased by +14.89% |
| Mar 8, 23 | -0.99 Increased by +40.36% | -1.02 Increased by +2.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 90.38 M Increased by +89.37% | -14.23 M Increased by +39.65% | Decreased by -15.75% Increased by +68.13% |
| Jun 30, 24 | 77.88 M Increased by +107.68% | -24.64 M Increased by +66.72% | Decreased by -31.64% Increased by +83.98% |
| Mar 31, 24 | 69.22 M Increased by +119.07% | -25.28 M Increased by +16.10% | Decreased by -36.52% Increased by +61.70% |
| Dec 31, 23 | 69.55 M Increased by +149.24% | -33.15 M Increased by +9.01% | Decreased by -47.66% Increased by +63.49% |
| Sep 30, 23 | 47.73 M Increased by +154.13% | -23.59 M Increased by +33.94% | Decreased by -49.42% Increased by +74.00% |
| Jun 30, 23 | 37.50 M Increased by +114.46% | -74.04 M Decreased by -175.01% | Decreased by -197.45% Decreased by -28.23% |
| Mar 31, 23 | 31.60 M Increased by +145.10% | -30.13 M Increased by +17.69% | Decreased by -95.35% Increased by +66.42% |
| Dec 31, 22 | 27.91 M Increased by +789.29% | -36.43 M Decreased by -163.31% | Decreased by -130.55% Decreased by -107.12% |